Unlocking methodological insights on oncology efficacy endpoints: from statistical to clinical and vice versa. Letter to the editor regarding 'Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3' by M. P. Goetz et al.

Autor:	De Sanctis R; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan; Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan. Electronic address: rita.de_sanctis@hunimed.eu., Bruzzi P; Department of Health Sciences, University of Genoa, Genova, Italy., Zambelli A; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan; Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan.
Jazyk:	angličtina
Zdroj:	Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2024 Dec; Vol. 35 (12), pp. 1201-1202. Date of Electronic Publication: 2024 Sep 03.
DOI:	10.1016/j.annonc.2024.08.2345
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu